|
US20170333435A1
(en)
|
2014-11-06 |
2017-11-23 |
Lysosomal Therapeutics Inc. |
Substituted imidazo[1,5-a]pyrimidines and their use in the treatment of medical disorders
|
|
US20180185368A1
(en)
|
2014-11-06 |
2018-07-05 |
Lysosomal Therapeutics Inc. |
Substituted pyrrolo[1,2-a]pyrimidines and their use in the treatment of medical disorders
|
|
EP4406616A3
(en)
|
2014-11-06 |
2024-11-06 |
Bial-R&D Investments, S.A. |
Substituted pyrazolo(1,5-a)pyrimidines and their use in the treatment of medical disorders
|
|
CA3020305A1
(en)
|
2016-04-06 |
2017-10-12 |
Lysosomal Therapeutics Inc. |
Imidazo [1,5-a]pyrimidinyl carboxamide compounds and their use in the treatment of medical disorders
|
|
EP3440081A4
(en)
|
2016-04-06 |
2019-09-18 |
Lysosomal Therapeutics Inc. |
PYRROLO [1,2-A] PYRIMIDINYL-CARBOXAMIDE COMPOUNDS AND THEIR USE IN THE TREATMENT OF MEDICAL DISORDER
|
|
AU2017246455B2
(en)
|
2016-04-06 |
2021-09-30 |
Bial - R&D Investments, S.A. |
Pyrazolo[1,5-a]pyrimidinyl carboxamide compounds and their use in the treatment of medical disorders
|
|
KR102530515B1
(ko)
|
2016-05-05 |
2023-05-09 |
비알 - 알&디 인베스트먼츠, 에스.에이. |
치환된 이미다조[1,2-b]피리다진, 치환된 이미다조[1,5-b]피리다진, 관련 화합물, 및 의학적 장애의 치료에서의 그의 용도
|
|
ES2902995T3
(es)
*
|
2016-10-07 |
2022-03-30 |
Bristol Myers Squibb Co |
Compuestos de imidazopiridazina útiles como moduladores de respuestas a IL-12, IL-23 y/o IFN alfa
|
|
EP3541817B1
(en)
*
|
2016-11-17 |
2020-12-23 |
Bristol-Myers Squibb Company |
Imidazopyridazine modulators of il-12, il-23 and/or ifn-alpha
|
|
SI3658557T1
(sl)
*
|
2017-07-28 |
2024-10-30 |
Takeda Pharmaceutical Company Limited |
Zaviralci TYK2 in njihova uporaba
|
|
AR117398A1
(es)
|
2018-03-12 |
2021-08-04 |
Abbvie Inc |
Inhibidores de la señalización mediada por tirosina cinasa 2
|
|
JP7179161B2
(ja)
*
|
2018-09-10 |
2022-11-28 |
イーライ リリー アンド カンパニー |
乾癬および全身性エリテマトーデスの処置に有用なピラゾロ［１，５－ａ］ピリミジン－３－カルボキサミド誘導体
|
|
JP7631193B2
(ja)
|
2018-10-22 |
2025-02-18 |
アルミス インコーポレイテッド |
Ｔｙｋ２阻害剤およびその使用
|
|
AR117177A1
(es)
|
2018-12-10 |
2021-07-14 |
Lilly Co Eli |
DERIVADOS DE 7-(METILAMINO)PIRAZOLO[1,5-A]PIRIMIDIN-3-CARBOXAMIDA COMO INHIBIDORES DE IL-23 E INFa
|
|
TWI752400B
(zh)
*
|
2019-01-07 |
2022-01-11 |
美商美國禮來大藥廠 |
Il-17a抑制劑
|
|
CN113348021B
(zh)
*
|
2019-01-23 |
2025-07-11 |
武田药品工业株式会社 |
Tyk2抑制剂和其用途
|
|
JP2022519696A
(ja)
*
|
2019-02-07 |
2022-03-24 |
ベンティックス バイオサイエンシーズ，インク． |
Ｔｙｋ２偽キナーゼリガンド
|
|
US12473290B2
(en)
|
2019-03-05 |
2025-11-18 |
Bristol Myers-Squibb Company |
Imidazopyridazine compounds useful as modulators of IL-12, IL-23 and/or IFN alpha responses
|
|
CA3132632A1
(en)
*
|
2019-03-11 |
2020-09-17 |
Esker Therapeutics, Inc. |
Tyk2 inhibitors and uses thereof
|
|
TWI810520B
(zh)
|
2020-02-12 |
2023-08-01 |
美商美國禮來大藥廠 |
7-(甲基胺基)吡唑并[1,5-a]嘧啶-3-甲醯胺化合物
|
|
CN115052660B
(zh)
|
2020-02-12 |
2024-01-09 |
伊莱利利公司 |
取代的7-(甲氨基)吡唑并[1,5-a]嘧啶-3-甲酰胺衍生物
|
|
CN115867348B
(zh)
*
|
2020-04-30 |
2025-05-06 |
詹森药业有限公司 |
作为il-17调节剂的咪唑并嘧啶
|
|
PE20230469A1
(es)
*
|
2020-04-30 |
2023-03-14 |
Janssen Pharmaceutica Nv |
Imidazopiridazinas como moduladores de il-17
|
|
EP3944859A1
(en)
|
2020-07-30 |
2022-02-02 |
Assistance Publique Hôpitaux de Paris |
Method for treating immune toxicities induced by immune checkpoint inhibitors
|
|
CN115916207A
(zh)
*
|
2020-08-20 |
2023-04-04 |
轶诺(浙江)药业有限公司 |
一类五元并六元杂环化合物及其作为蛋白受体激酶抑制剂的用途
|
|
EP4214215A1
(en)
*
|
2020-09-16 |
2023-07-26 |
Alumis Inc. |
Tyk2 inhibitors and uses thereof
|
|
WO2022156657A1
(en)
*
|
2021-01-19 |
2022-07-28 |
Anrui Biomedical Technology (Guangzhou) Co., Ltd. |
Imidazolopyridazine or pyrazolopyrimidine compounds and compositions
|
|
CA3213816A1
(en)
|
2021-03-16 |
2022-09-22 |
Anrui Biomedical Technology (Guangzhou) Co., Ltd. |
Amino heteroaryl compounds and compositions
|
|
EP4423086A1
(en)
|
2021-10-25 |
2024-09-04 |
Kymera Therapeutics, Inc. |
Tyk2 degraders and uses thereof
|
|
CN118580191A
(zh)
*
|
2022-01-28 |
2024-09-03 |
和记黄埔医药（上海）有限公司 |
用于制备咪唑并[1,2-b]哒嗪类化合物的中间体
|
|
WO2025168035A1
(zh)
*
|
2024-02-07 |
2025-08-14 |
合肥羿科医药有限公司 |
杂环类化合物、其药物组合物及其应用
|